Lyme vaccine hits 70%+ protection in phase 3

• 73.2% efficacy from 28 days after dose 4
• 74.8% efficacy from 1 day after dose 4
• Participants were age 5+
• No major safety signal was flagged at the time of analysis

There is one important nuance: the trial had a strict statistical checkpoint in its first primary analysis (confidence interval lower bound had to be above 20), and that exact bar was not met there, partly because fewer Lyme cases occurred than expected. But in the second pre-specified analysis, the lower bound was above 20, and Pfizer/Valneva say the overall efficacy signal remains clinically meaningful.